Immunomedics, Inc. (NASDAQ:IMMU) Files An 8-K Other Events
Item8.01. Other Events
On February 10, 2017, Immunomedics, Inc. (the Company) issued a
press release announcing it has postponed the Companys 2016
Annual Meeting of Stockholders (the 2016 Annual Meeting)
previously scheduled for February 16, 2017. As stated in the
press release, the Annual Meeting has been postponed to March 3,
2017 at 10:00 a.m. Eastern Time and will be held at the Executive
Offices of Immunomedics, Inc., located at 300 The American Road,
Morris Plains, New Jersey 07950. The record date of January 24,
2017 has not changed.
The full text of the press release is attached to this current
report on Form8-K as Exhibit99.1 and is incorporated by reference
herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description of Exhibit |
|
| 99.1 |
Press Release of Immunomedics, Inc., dated February 10, 2017, titled Immunomedics Announces Postponement of 2016 Annual Meeting |
About Immunomedics, Inc. (NASDAQ:IMMU)
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials. Immunomedics, Inc. (NASDAQ:IMMU) Recent Trading Information
Immunomedics, Inc. (NASDAQ:IMMU) closed its last trading session 00.00 at 4.30 with 1,189,332 shares trading hands.
